These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 30078201)

  • 1. Oxidative stress and neuroinflammation in the story of Parkinson's disease: Could targeting these pathways write a good ending?
    Hassanzadeh K; Rahimmi A
    J Cell Physiol; 2018 Jan; 234(1):23-32. PubMed ID: 30078201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combating Parkinson's disease with plant-derived polyphenols: Targeting oxidative stress and neuroinflammation.
    Gahtani RM; Shoaib S; Hani U; Jayachithra R; Alomary MN; Chauhan W; Jahan R; Tufail S; Ansari MA
    Neurochem Int; 2024 Sep; 178():105798. PubMed ID: 38950626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor erythroid 2-related factor 2 signaling in Parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death.
    Kumar H; Koppula S; Kim IS; More SV; Kim BW; Choi DK
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1015-29. PubMed ID: 23244425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's Disease.
    Sita G; Hrelia P; Tarozzi A; Morroni F
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism.
    Lee Y; Kim MS; Lee J
    Arch Pharm Res; 2017 Oct; 40(10):1117-1128. PubMed ID: 28952032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review.
    Bjørklund G; Dadar M; Anderson G; Chirumbolo S; Maes M
    Pharmacol Res; 2020 Nov; 161():105065. PubMed ID: 32652199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease.
    Jiang T; Sun Q; Chen S
    Prog Neurobiol; 2016 Dec; 147():1-19. PubMed ID: 27769868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free-radical toxicity and antioxidant medications in Parkinson's disease.
    Ciccone CD
    Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
    [No Abstract]   [Full Text] [Related]  

  • 9. Plant Polyphenols as Neuroprotective Agents in Parkinson's Disease Targeting Oxidative Stress.
    Hor SL; Teoh SL; Lim WL
    Curr Drug Targets; 2020; 21(5):458-476. PubMed ID: 31625473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status and future directions of clinical trials in Parkinson's disease.
    Söderbom G
    Int Rev Neurobiol; 2020; 154():153-188. PubMed ID: 32739003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroprotective effect of baicalein in patients with Parkinson's disease].
    Yu X; He G; Du G
    Zhongguo Zhong Yao Za Zhi; 2012 Feb; 37(4):421-5. PubMed ID: 22667137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anti-inflammatory therapy for Parkinson's disease.
    Gao HM; Liu B; Zhang W; Hong JS
    Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic implications of crocin in Parkinson's disease: A review of preclinical research.
    Goyal A; Verma A; Agrawal A; Dubey N; Kumar A; Behl T
    Chem Biol Drug Des; 2023 Jun; 101(6):1229-1240. PubMed ID: 36752710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.
    Jin H; Kanthasamy A; Ghosh A; Anantharam V; Kalyanaraman B; Kanthasamy AG
    Biochim Biophys Acta; 2014 Aug; 1842(8):1282-94. PubMed ID: 24060637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of cannabidiol in Parkinson's disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation.
    Vallée A; Vallée JN; Lecarpentier Y
    Aging (Albany NY); 2021 Apr; 13(7):10796-10813. PubMed ID: 33848261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease.
    Azam F; Barodia SK; Anwer T; Alam MM
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):808-17. PubMed ID: 18846462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression.
    Youdim MB; Grünblatt E; Levites-Royak Y; Mandel S
    Adv Neurol; 2001; 86():115-24. PubMed ID: 11553968
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease.
    Taylor JM; Main BS; Crack PJ
    Neurochem Int; 2013 Apr; 62(5):803-19. PubMed ID: 23291248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View.
    Filograna R; Beltramini M; Bubacco L; Bisaglia M
    Curr Neuropharmacol; 2016; 14(3):260-71. PubMed ID: 26517052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.
    Little JP; Villanueva EB; Klegeris A
    Mini Rev Med Chem; 2011 Jun; 11(7):582-90. PubMed ID: 21699489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.